Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why TLRY Stock Is at a Positive Turning Point

By Chris Lau, InvestorPlace Contributor

Tilray has high costs to overcome first as it builds its brand recognition in the U.S. market and ahead of the Federal cannabis legalization.

Why SoFi Technologies Is Down by so Much

By Chris Lau, InvestorPlace Contributor

Inflation is driving rate hikes for 2022, which is scaring investors from buying emerging fintech names like SOFI stock.

Investors Cannot Ignore this One Red Flag on AMC Entertainment

By Chris Lau, InvestorPlace Contributor

Markets will avoid companies like AMC stock with broken business models, as cash burn rates continue for the next few quarters.

Here Is Why Palantir Is Plunging

By Chris Lau, InvestorPlace Contributor

Heavy stock-based compensation hurts PLTR stock investors as technology investors dump companies that have little to no profits.

7 Stocks to Buy That Are Nowhere Near Being Overvalued

By Chris Lau, InvestorPlace Contributor

These stocks to buy are above their lows and appear overvalued. They have more upside as growth drivers emerge lifting their prospects.

Load More